Q Biomed (OTCMKTS:QBIO) & Auna (NYSE:AUNA) Head to Head Review

Auna (NYSE:AUNA) and Q Biomed (OTCMKTS:QBIO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends.

Volatility & Risk

Auna has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Q Biomed has a beta of 2.51, suggesting that its stock price is 151% more volatile than the S&P 500.

Earnings and Valuation

This table compares Auna and Q Biomed”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auna	$1.17 billion	0.29	$29.39 million	$0.71	6.51
Q Biomed	N/A	N/A	N/A	$0.08	N/A

Auna has higher revenue and earnings than Q Biomed. Q Biomed is trading at a lower price-to-earnings ratio than Auna, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Auna and Q Biomed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auna	4.40%	13.52%	3.27%
Q Biomed	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Auna and Q Biomed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auna	1	4	1	0	2.00
Q Biomed	0	0	0	0	0.00

Auna currently has a consensus target price of $7.63, indicating a potential upside of 65.22%. Given Auna’s stronger consensus rating and higher possible upside, analysts plainly believe Auna is more favorable than Q Biomed.

Summary

Auna beats Q Biomed on 8 of the 9 factors compared between the two stocks.

About Auna

Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.

About Q Biomed

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.